<DOC>
	<DOCNO>NCT00343421</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity Pediacel® infants toddler give 2,3,4 12-18 month age . Primary Objectives : - To compare post-dose 3 immunogenicity Pediacel® Infanrix®-IPV+Hib co-administered Prevenar® . - To describe post-dose 3 pertussis antibody response . Secondary Objectives : - To compare post-dose 4 immunogenicity Pediacel® Infanrix®-IPV+Hib co-administered Prevenar® . - To describe safety vaccination follow co-administration Prevenar® .</brief_summary>
	<brief_title>Study Compare Pediacel® Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® Infants Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants 55 75 day old , inclusive day first vaccination Born full term pregnancy ( &gt; 37 week ) Informed consent form sign parent ( ) legal guardian Parents legal guardian able read write local language Parent ( ) legal guardian able attend schedule visit comply study procedure . Presence fever ( defined rectal body temperature ≥ 38.0°C ) report within last 72 hour Moderate severe acute illness without fever Participation another clinical trial 30 day precede first study vaccination Planned participation another clinical trial present study period Received diphtheria , tetanus , pertussis , poliomyelitis , Haemophilus influenzae type b pneumococcal vaccine separately combination prior study vaccination Received vaccination 30 day precede first study vaccination and/or plan vaccination within 6 week follow study vaccination Congenital acquire humoral/cellular immunodeficiency immunosuppressive therapy longterm systemic corticosteroid therapy ( ≥ 2 mg/kg/day prednisone equivalent ≥ 14 day ) previous 30 day Systemic local hypersensitivity study vaccine component ( include neomycin , streptomycin , polymyxin B formaldehyde ) History lifethreatening reaction ( ) ( encephalopathy , HypotonicHyporesponsive Episode , rectal body temperature ≥ 40.0°C , convulsion without fever ) vaccine contain component study vaccine Blood bloodderived product ( immunoglobulin ) receive since birth Known Human immunodeficiency virus ( HIV ) seropositivity Known thrombocytopenia bleed disorder contraindicate intramuscular vaccination History encephalopathy , seizures progressive , evolve unstable neurological condition Clinically significant finding review system might interfere study vaccination , opinion Investigator , would interfere evaluation study vaccine/objectives pose health risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>75 Days</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Pneumococcal infection</keyword>
</DOC>